BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$179.89
3.71 (2.11%)
ā²
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Feb 06, 2026
5d
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
ā BUY SIGNAL: BIIB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
ā BUY SIGNAL: BIIB shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$337.61
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$209.63
14.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $179.89, which is considered slightly high relative to its 30-day fair value range of $170.24 to $182.10. The stock's valuation (Forward PE: 11.7) is in line with its historical norms (11.5). At these levels, the market is pricing in 0.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BIIB is in a strong uptrend. The price is approaching resistance at $180.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIIB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BIIB is in a strong uptrend. The price is approaching resistance at $180.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIIB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$170.24 -
$182.10
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($192.31)
- NEUTRAL: Market pricing in 0.6% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$170.24 -
$182.10
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
Ā±$7.56
(4.2%)
Support & Resistance Levels
Support Level
$160.36
Resistance Level
$180.14
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
11.69
Wall Street Target
$192.31
(+9.2%)
Revenue Growth (YoY)
2.8%
Earnings Growth (YoY)
19.2%
Profit Margin
16.0%
Valuation Premium vs History
+0.6% premium
PE vs Historical
11.7 vs 11.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.6%
(market-implied from PE analysis)
1-Year Target
$177.24
(+1%)
2-Year Target
$178.30
(+1%)
3-Year Target
$179.37
(+2%)
3-Yr Target (if PE normalizes)
(PE: 12ā12)
PE COMPRESSION
$176.51
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 34.6%)
$339.68
(+93%)
Base:
(SPY PE: 11.7, Growth: 34.6%)
$178.02
(+1%)
Bear:
(PE: 9.9, Growth: 34.6%)
$151.31
(-14%)
š
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 15.94 | Current EPS (TTM): $10.97
Bull Case
$264.28
(+47%)
Analyst growth 37.4%, PE expands to 17.5
Base Case
$240.26
(+34%)
Market implied 37.4%, PE stable at 15.9
Bear Case
$118.88
(-34%)
Severe decline -20.0%, PE contracts to 13.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 5:17 AM ET
Data refreshes hourly during market hours. Next update: 6:17 AM
Data refreshes hourly during market hours. Next update: 6:17 AM
š„ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
1
Buys
1
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Priya Singhal
SELL
517 shares
2025-09-02
Ro Khanna
BUY
2025-08-26
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1111 | 60 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$135 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$332 | 66 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$245 | 61 BUY |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$115 | 60 HOLD |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
